<DOC>
	<DOCNO>NCT02529293</DOCNO>
	<brief_summary>This double-blinded , randomised , single-centre phase I pilot trial explore feasibility pivotal clinical trial establish bioequivalence BioChaperone insulin lispro U-200 BioChaperone insulin lispro U-100 healthy subject . Each subject randomly allocate sequence four treatment , i.e . two single dos BioChaperone insulin lispro U-200 0.2 U·kg BW-1 two single dos BioChaperone insulin lispro U-100 0.2 U·kg BW-1 four separate dose visit .</brief_summary>
	<brief_title>A Clinical Trial Investigating Intra-subject Variability Pharmacokinetics Glucodynamics BioChaperone Insulin Lispro U-100 Product U-200 Product Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Male female subject , consider generally healthy upon completion medical history , physical examination biochemical investigation judge Investigator . Age ≥ 18 ≤ 64 year , inclusive . Body Mass Index ( BMI ) 18.5 28.0 kg∙m2 , inclusive . Fasting Plasma Glucose ( FPG ) ≤ 5.6 mmol/L ( 100 mg/dL ) . Signed date informed consent obtain trialrelated activity , i.e . procedure would perform normal management subject ) . Known suspected hypersensitivity trial product ( ) relate product . Receipt investigational medicinal product within 3 month randomisation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>